反苯环丙胺
参考资料

1 2 3  Williams, David A. . Foye, William O.; Lemke, Thomas L.; Williams, David A.  (编). . Hagerstwon, MD: Lippincott Williams & Wilkins. 2007: 590–1  [2009-09-03]. ISBN 0-7817-6879-9. （原始内容存档于2017-09-08）.
1 2  Ulrich, Sven; Ricken, Roland; Adli, Mazda. . European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology. 08 2017, 27 (8): 697–713  [2018-10-17]. ISSN 1873-7862. PMID 28655495. doi:10.1016/j.euroneuro.2017.05.007. （原始内容存档于2018-10-17）.  请检查|date=中的日期值 (帮助)
↑  . Drugs of the Future. 2015, 40 (11): 771. ISSN 0377-8282. doi:10.1358/dof.2015.040.11.2413472.
1 2 3  Riederer, P; Laux, G (March 2011). . Experimental Neurobiology. 2011,. 20 (1): 1 (1): 17  [2018-10-17]. ISSN 1226-2560. PMC 3213739 . PMID 22110357. doi:10.5607/en.2011.20.1.1. （原始内容存档于2020-11-11） （英语）.
↑  Zametkin A, Rapoport JL, Murphy DL, Linnoila M, Ismond D. Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy. Arch Gen Psychiatry. 1985 Oct;42(10):962-6. doi: 10.1001/archpsyc.1985.01790330042005. PMID: 3899047.
↑  Levin GM. Attention-deficit hyperactivity disorder: the pharmacist's role. Am Pharm. 1995 Nov;NS35(11):10-20. PMID: 8533716.
1 2 3 4  UK Electronic medicines compendium. Tranylcypromine （页面存档备份，存于）
↑  Gillman, PK (February 2011). "Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors". Journal of Clinical Psychopharmacology. 31 (1): 66–74.
1 2 3 4 5 6 7 8 9  Ulrich, Sven; Ricken, Roland; Adli, Mazda. . European Neuropsychopharmacology (Elsevier BV). 2017, 27 (8): 697–713. ISSN 0924-977X. doi:10.1016/j.euroneuro.2017.05.007.
1 2 3 4 5 6  Gillman, Peter Kenneth. . Journal of Clinical Psychopharmacology (Ovid Technologies (Wolters Kluwer Health)). 2011, 31 (1): 66–74. ISSN 0271-0749. doi:10.1097/jcp.0b013e31820469ea.
1 2 3 4 5 6  Ricken, Roland; Ulrich, Sven; Schlattmann, Peter; Adli, Mazda. . European Neuropsychopharmacology (Elsevier BV). 2017, 27 (8): 714–731. ISSN 0924-977X. doi:10.1016/j.euroneuro.2017.04.003.
↑  van Haelst, Ingrid M. M.; van Klei, Wilton A.; Doodeman, Hieronymus J.; Kalkman, Cor J.; Egberts, Toine C. G. . The Journal of Clinical Psychiatry (Physicians Postgraduate Press, Inc). 2012-07-10, 73 (08): 1103–1109. ISSN 0160-6689. doi:10.4088/jcp.11m07607.
↑  Smith, Mark Stafford; Muir, Holly; Hall, Richard. . Drugs (Springer Science and Business Media LLC). 1996, 51 (2): 238–259. ISSN 0012-6667. doi:10.2165/00003495-199651020-00005.
↑  Blom-Peters, L; Lamy, M (1993). "Monoamine oxidase inhibitors and anesthesia: an updated literature review". Acta Anaesthesiologica Belgica. 44 (2): 57–60. PMID 8237297.
↑  Le Gassicke, J.; Ashcroft, G. W.; Eccleston, D.; Evans, J. I.; Oswald, I.; Ritson, E. B. . British Journal of Psychiatry (Royal College of Psychiatrists). 1965, 111 (473): 357–364. ISSN 0007-1250. doi:10.1192/bjp.111.473.357.
↑  Williams, David A. (2007). "Antidepressants". In Foye, William O.; Lemke, Thomas L.; Williams, David A. Foye's Principles of Medicinal Chemistry. Hagerstwon, USA: Lippincott Williams & Wilkins. pp. 590–1. ISBN 978-0-7817-6879-5.
↑  Lee, MG; Wynder, C; Schmidt, DM; McCafferty, DG; Shiekhattar, R (June 2006). "Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications". Chemistry & Biology. 13 (6): 563–7.
↑  Mast, Natalia; Charvet, Casey; Pikuleva, Irina A.; Stout, C. David. . Journal of Biological Chemistry (Elsevier BV). 2010, 285 (41): 31783–31795. ISSN 0021-9258. doi:10.1074/jbc.m110.143313.
↑  Sherry, R.L; Rauw, G; McKenna, K.F; Paetsch, P.R; Coutts, R.T; Baker, G.B. . Journal of Affective Disorders (Elsevier BV). 2000, 61 (1-2): 23–29. ISSN 0165-0327. doi:10.1016/s0165-0327(99)00188-3.
↑  V.J. Rajadhyaksha, US Patent 4016204 (1977).
↑  A. Burger, W.L.L. Yost. . J. Am. Chem. Soc. 1948, 70: 2198. doi:10.1021/ja01186a062.